Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of General Internal Medicine
Published in: Journal of General Internal Medicine 9/2019

01-09-2019 | Care | Letter to the Editor

Abnormal Liver Enzymes

Authors: John Bian, Ph.D., Andrew D. Schreiner, M.D., M.S.C.R., Don C. Rockey, M.D.

Published in: Journal of General Internal Medicine | Issue 9/2019

Login to get access

Excerpt

We appreciate the insightful comments by Dr. Lai on our study of associations of race with follow-up patterns after an initial abnormal liver test of patients in a primary care setting.1, 2 Here, we would like to reiterate our strong support of vigilant reevaluation following an initial abnormal liver test in primary care, a practice recommended by the American College of Gastroenterology.3 …
Literature
1.
Lai SW. Abnormal liver enzymes. J Gen Intern Med. (MS#26828).
2.
Bian J, Schreiner AD, Zhang J, et al. Associations of Race with Follow-up Patterns After Initial Abnormal Liver Tests in Primary Care. J Gen Intern Med. 2018;22(10):1618–1620.CrossRef
3.
Kwo PY, Cohen SM, Lim JK. ACG Clinical guideline: evaluation of abnormal liver chemistries. Am J Gastroenterol. 2017;112(1):18–35.CrossRef
4.
Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–357.CrossRef
5.
Alexander M, Loomis AK, Fairburn-Beech J, et al. Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease. BMC Medicine. 2018;16(1):130.CrossRef
Metadata
Title
Abnormal Liver Enzymes
Authors
John Bian, Ph.D.
Andrew D. Schreiner, M.D., M.S.C.R.
Don C. Rockey, M.D.
Publication date
01-09-2019
Publisher
Springer US
Keyword
Care
Published in
Journal of General Internal Medicine / Issue 9/2019
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-019-05172-7

Other articles of this Issue 9/2019

Journal of General Internal Medicine 9/2019 Go to the issue

Capsule Commentary

Capsule Commentary on Jetelina et al., Patient-Reported Barriers to Completing a Diagnostic Colonoscopy Following Abnormal Fecal Immunochemical Test among Uninsured Patients

Original Research

Patient-Reported Barriers to Completing a Diagnostic Colonoscopy Following Abnormal Fecal Immunochemical Test Among Uninsured Patients

OriginalPaper

The Impact of Medicaid Expansion on Continuous Enrollment: a Two-State Analysis

Original Research

Real-time Feedback in Pay-for-Performance: Does More Information Lead to Improvement?

Capsule Commentary

Capsule Commentary on Gordon et al., The Impact of Medicaid Expansion on Continuous Enrollment: a Two-State Analysis

OriginalPaper

State Governments and Judges May Moderate the Impact of the Trump Administration’s Promotion of Medicaid Work Requirements
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits